Search

Your search keyword '"Treves, S."' showing total 862 results
Start Over Author "Treves, S." Publication Type Academic Journals
862 results on '"Treves, S."'

1. Development and autoregulation of kidney function in children: a retrospective study using .sup.99mTc-MAG3 renography

Author

Cao, Xinhua, Xu, Xiaoyin, Treves, S. Ted, Drubach, Laura A., Kwatra, Neha, Zhang, Min, and Fahey, Frederic H.

Subjects
Kidney function tests -- Demographic aspects, Technetium -- Isotopes, Kidney diseases -- Diagnosis -- Risk factors -- Demographic aspects, Health
Abstract

Background Both the development of kidney function in healthy children and autoregulation ability of kidney function in patients with asymmetric kidneys are important in clinical diagnosis and treatment of kidney-related diseases, but there are however only limited studies. This study aimed to investigate development of kidney function in normal children with healthy symmetric kidneys and autoregulation of the healthy kidney compensating the functional loss of a diseased one in children with asymmetric kidneys. Methods Two hundred thirty-seven children (156 male, 81 female) from 0 to 20y (average 4.6y ± 5.1) undergoing .sup.99mTc-MAG3 renography were included, comprising 134 with healthy symmetrically functioning kidneys and 103 with asymmetric kidneys. Clearance was calculated from kidney uptakes at 1-2 min. A developmental model between MAG3 clearance (CL) and patient age in normal group was identified (CL = 84.39Age.sup.0.395 ml/min, r = 0.957, p < 0.001). The clearance autoregulation rate in abnormal group with asymmetric kidneys was defined as the ratio of the measured MAG3 clearance and the normal value predicted from the renal developmental model of normal group. Results No significant difference of MAG3 clearance (p = 0.723) was found between independent abnormal group and normal group. The autoregulation rate of kidney clearance in abnormal group was 94.2% on average, and no significant differences were found between two age groups (p = 0.49), male and female (p = 0.39), and left kidney and right kidney (p = 0.92) but two different grades of asymmetric kidneys (p = 0.02). Conclusions The healthy kidney of two asymmetric kidneys can automatically regulate total kidney function up to 94% of two symmetric kidneys in normal children. Graphical abstract, Author(s): Xinhua Cao [sup.1] , Xiaoyin Xu [sup.2] , S. Ted Treves [sup.2] , Laura A. Drubach [sup.1] , Neha Kwatra [sup.1] , Min Zhang [sup.2] , Frederic H. Fahey [...]

Published
2022
Full Text
View/download PDF

3. SNMMI procedure standard/EANM practice guideline on pediatric [99mTc]Tc-DMSA renal cortical scintigraphy: an update

Author

Vali, Reza, Armstrong, Ian S., Bar-Sever, Zvi, Biassoni, Lorenzo, Borgwardt, Lise, Brown, Justin, Grant, Frederick D., Mandell, Gerald A., Majd, Massoud, Nadel, Helen R., Ng, Thomas S. C., Roca-Bielsa, Isabel, Rohringer, Taryn J., Santos, Ana Isabel, Seghers, Victor, Shaikh, Nader, Ted Treves, S., Zaffino-Nevrotski, Teresa, Zucchetta, Pietro, and Lim, Ruth

Published
2022
Full Text
View/download PDF

4. Review of the Clinical and Technical Aspects of 99mTc-Dimercaptosuccinic Acid Renal Imaging: The Comeback "Kit".

Author

Lim, Ruth, Kwatra, Neha, Ferrer Valencia, Valentina, Collins, Katelyn N., Vali, Reza, Fahey, Frederic H., and Treves, S. Ted

Abstract

99mTc-labeled dimercaptosuccinic acid (99mTc-DMSA) imaging is a well-established and highly sensitive method for the diagnosis of several renal cortical disorders affecting children and adults. Beginning in 2014, 99mTc-DMSA availability was severely impaired when it was added to the Drug Shortages List of the U.S. Food and Drug Administration and was commercially unavailable thereafter. The agent shortage negatively impacted practitioners' ability to evaluate renal cortical defects in children and adults and changed renal imaging practice. A survey among pediatric nuclear medicine clinicians confirmed the clinical need for 99mTc-DMSA. Finally, in early 2023 the Food and Drug Administration again approved 99mTc-DMSA in the United States. During the 99mTc-DMSA shortage, established practitioners may not have had the opportunity of using 99mTc-DMSA as they were accustomed in their experience. Also, newer imaging specialists and referring physicians and technologists may not have benefited from having 99mTc-DMSA in their training. Therefore, it is time to bring back 99mTc-DMSA into the armamentarium of imaging methods available to evaluate regional cortical renal function. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Renal 99mTc-DMSA pharmacokinetics in pediatric patients

Author

Plyku, Donika, Ghaly, Michael, Li, Ye, Brown, Justin L., O’Reilly, Shannon, Khamwan, Kitiwat, Goodkind, Alison B., Sexton-Stallone, Briana, Cao, Xinhua, Zurakowski, David, Fahey, Frederic H., Treves, S. Ted, Bolch, Wesley E., Frey, Eric C., and Sgouros, George

Published
2021
Full Text
View/download PDF

20. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis

Author

Dlamini, N., Voermans, N.C., Lillis, S., Stewart, K., Kamsteeg, E.-J., Drost, G., Quinlivan, R., Snoeck, M., Norwood, F., Radunovic, A., Straub, V., Roberts, M., Vrancken, A.F.J.E., van der Pol, W.L., de Coo, R.I.F.M., Manzur, A.Y., Yau, S., Abbs, S., King, A., Lammens, M., Hopkins, P.M., Mohammed, S., Treves, S., Muntoni, F., Wraige, E., Davis, M.R., van Engelen, B., and Jungbluth, H.

Published
2013
Full Text
View/download PDF

38. Image Gently: progress and challenges in CT education and advocacy

Author

Goske, Marilyn J., Applegate, Kimberly E., Bulas, Dorothy, Butler, Priscilla F., Callahan, Michael J., Coley, Brian D., Don, Steven, Frush, Donald P., Hernanz-Schulman, Marta, Kaste, Sue C., Morrison, Gregory, Sidhu, Manrita, Strauss, Keith J., Treves, S. Ted, and on behalf of the Alliance for Radiation Safety in Pediatric Imaging

Published
2011
Full Text
View/download PDF

42. Costs and consequences of universal sibling screening for vesicoureteral reflux: decision analysis

Author

Routh, Jonathan C., Grant, Frederick D., Kokorowski, Paul, Lee, Richard S., Fahey, Frederic H., Treves, S. Ted, and Nelson, Caleb P.

Subjects
Bladder diseases -- Diagnosis, Bladder diseases -- Demographic aspects, Bladder diseases -- Research, Medical care, Cost of -- Research, Infants (Newborn) -- Medical examination, Infants (Newborn) -- Usage, Infants (Newborn) -- Economic aspects, Infants (Newborn) -- Research
Published
2010

45. Development and autoregulation of kidney function in children: a retrospective study using 99mTc-MAG3 renography.

Author

Cao, Xinhua, Xu, Xiaoyin, Treves, S. Ted, Drubach, Laura A., Kwatra, Neha, Zhang, Min, Fahey, Frederic H., Diamond, David A., and Voss, Stephan D.

Subjects
KIDNEY physiology, HOMEOSTASIS, HUMAN growth, RADIONUCLIDE angiography, RETROSPECTIVE studies, CHILDREN
Abstract

Background: Both the development of kidney function in healthy children and autoregulation ability of kidney function in patients with asymmetric kidneys are important in clinical diagnosis and treatment of kidney-related diseases, but there are however only limited studies. This study aimed to investigate development of kidney function in normal children with healthy symmetric kidneys and autoregulation of the healthy kidney compensating the functional loss of a diseased one in children with asymmetric kidneys. Methods: Two hundred thirty-seven children (156 male, 81 female) from 0 to 20y (average 4.6y ± 5.1) undergoing 99mTc-MAG3 renography were included, comprising 134 with healthy symmetrically functioning kidneys and 103 with asymmetric kidneys. Clearance was calculated from kidney uptakes at 1–2 min. A developmental model between MAG3 clearance (CL) and patient age in normal group was identified (CL = 84.39Age0.395 ml/min, r = 0.957, p < 0.001). The clearance autoregulation rate in abnormal group with asymmetric kidneys was defined as the ratio of the measured MAG3 clearance and the normal value predicted from the renal developmental model of normal group. Results: No significant difference of MAG3 clearance (p = 0.723) was found between independent abnormal group and normal group. The autoregulation rate of kidney clearance in abnormal group was 94.2% on average, and no significant differences were found between two age groups (p = 0.49), male and female (p = 0.39), and left kidney and right kidney (p = 0.92) but two different grades of asymmetric kidneys (p = 0.02). Conclusions: The healthy kidney of two asymmetric kidneys can automatically regulate total kidney function up to 94% of two symmetric kidneys in normal children. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

49. Positron emission tomography (PET) imaging of neuroblastoma and melanoma with [sup.64]Cu-SarAr immunoconjugates

Author

Voss, Stephan D., Smith, Suzanne V., DiBartolo, Nadine, McIlntosh, Lacey J., Cyr, Erika M., Bonab, Ali A., Dearling, Jason L.J., Carter, Edward A., Fischman, Alan J., Treves, S. Ted, Gillies, Stephen D., Sargeson, Alan M., Huston, James S., and Packard, Alan B.

Subjects
Neuroblastoma -- Diagnosis, PET imaging -- Usage, Melanoma -- Diagnosis, Science and technology
Abstract

The advancement of positron emission tomography (PET) depends on the development of new radiotracers that will complement [sup.18]F-FDG. Copper-64 ([sup.64]Cu) is a promising PET radionuclide, particularly for antibody-targeted imaging, but the high in vivo lability of conventional chelates has limited its clinical application. The objective of this work was to evaluate the novel chelating agent SarAr (1-N-(4-aminobenzyl)-3,6,10,13,16,19-hexaazabicyclo[6.6.6]- eicosane-1,8-diamine) for use in developing a new class of tumor-specific [sup.64]Cu radiopharmaceuticals for imaging neuroblastoma and melanoma. The anti-GD2 monoclonal antibody (mAb) 14.G2a, and its chimeric derivative, ch14.18, target disialogangliosides that are overexpressed on neuroblastoma and melanoma. Both mAbs were conjugated to SarAr using carbodiimide coupling. Radiolabeling with [sup.64]Cu resulted in >95% of the [sup.64]Cu being chelated by the immunoconjugate. Specific activities of at least 10 [micro]Ci/[micro]g (1 Ci = 37 GBq) were routinely achieved, and no additional purification was required after [sup.64]Cu labeling. Solid-phase radioimmuno-assays and intact cell-binding assays confirmed retention of bioactivity. Biodistribution studies in athymic nude mice bearing s.c. neuroblastoma (IMR-6, NMB-7) and melanoma (M21) xenografts showed that 15-20% of the injected dose per gram accumulated in the tumor at 24 hours after injection, and only 5-10% of the injected dose accumulated in the liver, a lower value than typically seen with other chelators. Uptake by a GD2-negative tumor xenograft was significantly lower (

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results